Taken together, this study has important implications for cancer research and immune-based therapeutics: (1) our highly specific, versatile α-LGR5 antibody is a particularly useful research tool for determining novel cell biology of human LGR5; (2) LGR5-expressing tumour cells have been validated as bone fide therapeutic targets in CRC, HCC and pre-B-ALL with the possibility of identifying further LGR5-expressing cancers types; and (3) the demonstration that α-LGR5 is an adaptable therapeutic antibody for targeting cancer cells in the ADC, BiTE and CAR-T-cell modalities. This evidence concerns the gene LGR5 and acute lymphoblastic leukemia.